Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)

Vikram Pothuri, Jorge G. Zárate Rodriguez, Christina Kasting, Natasha Leigh, William G. Hawkins, Dominic E. Sanford, Ryan C. Fields

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: The impact of neighborhood deprivation on outcomes in patients with pancreatic ductal adenocarcinoma (PDAC) is not well-described and represents an area to improve disparities. Methods: We retrospectively queried our prospectively maintained database of patients with PDAC (2014–2022). Patients were grouped by Area Deprivation Index (ADI) and rural-urban commuting area (RUCA) codes. Cox proportional hazards models and logistic regressions were used to investigate effect on overall survival (OS) and adjuvant therapy administration. Results: 536 patients were included. High ADI patients (more disadvantaged, n = 184) were more likely to identify as non-Hispanic Black (17.9% vs. 4.8%, p < 0.01) and were more likely to be from rural areas (49.5% vs. 18.5%, p < 0.01). High ADI was independently associated with decreased OS (HR (95% CI): 1.31 (1.01–1.69), p = 0.04). Urban high ADI patients were 3.5 times more likely to receive adjuvant therapy than rural high ADI patients (OR [95% CI]: 3.48 [1.26–9.61], p = 0.02). Discussion: Patients from the most disadvantaged neighborhoods have decreased OS. Access to adjuvant therapy likely contributes to this disparity in rural areas. Investigation into sources of this OS disparity and identification of barriers to adjuvant therapy will be crucial to improve outcomes in underserved patients with PDAC.

Original languageEnglish
Pages (from-to)1545-1554
Number of pages10
JournalHPB
Volume25
Issue number12
DOIs
StatePublished - Dec 2023

Fingerprint

Dive into the research topics of 'Area deprivation and rurality impact overall survival and adjuvant therapy administration in patients with pancreatic ductal adenocarcinoma (PDAC)'. Together they form a unique fingerprint.

Cite this